Transgene plans to use the tests from Ventana and Beckman Coulter to analyze which subpopulations of patients with advanced NSCLC will likely respond best to the MVA-MUC1-IL2 immunotherapeutic in combination with first-line therapy.
Insight is developing the tests using TaqMan probes on Life Technologies' ABI 7500 Fast Dx real-time PCR system to help physicians monitor cancer patients for mutations and upregulation in the ALK gene in order to make more effective treatment decisions.
In the study, out of three patients with ALK gene rearrangements, two responded partially to Infinity's investigational drug IPI-504, and one experienced prolonged stable disease while on the treatment for 7.2 months and had a 24 percent reduction in tumor size.
Although OncoMethylome could not disclose the specific drug development program for which its DNA methylation-specific PCR biomarker will be used, GSK's pipeline offers some hints as to the specific immunotherapeutic involved.
Despite pleas of breast cancer advocates to maintain access to Avastin using gene markers to identify those most likely to benefit, there is little evidence to suggest that the drug company or regulatory experts are considering this strategy.